MIVOLIS Sweetener Tablets 2400 pcs. - Table Sweeteners | Germany

Product Information

If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous. Side effects

MOVALIS is used to treat the symptoms of osteoarthritis. This disease mainly affect the joints causing pain and swelling. Moderate] Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.All medicines have benefits and risks. Your doctor has weighed the risks of you taking MOVALIS against the benefits they expect it will have for you. Hipersensibilitate la meloxicam sau orice excipient al medicamentului. Este posibila sensibilitatea incrucisata cu acidul acetilsalicilic sau cu alte ains. Movalis nu trebuie administrat pacientilor care prezinta semne de astm, polipi nazali, angioedem sau urticarie, urmare a administrarii de acid acetilsalicilic sau alt antiinflamator; in caz de ulcer peptic activ, insuficienta hepatica severa, insuficienta renala severa nedializata, copii si adolescentii sub 15 ani, sarcina sau alaptare.

Litiu: AINS cresc concentraţiile plasmatice de litiu (prin scăderea excreţiei renale a litiului), care poate atinge valori toxice. Nu se recomandă administrarea concomitentă de litiu şi AINS. Dacă este necesară această asociere trebuie monitorizată cu atenţie concentratia litiului plasmatic atunci când se iniţiază, se modifică sau se întrerupe tratamentul cu meloxicam. Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for Movalis.NSAIDs should be prescribed with caution in patients with a prior history of recent ulcer disease or GI bleeding. Carcinogenicity. Two year dietary studies showed no evidence for carcinogenic activity at meloxicam doses up to 0.8 mg/kg/day (approximately half of the highest human dose at 15 mg/day for a 50 kg person based on body surface area [BSA]) in rats and up to 8 mg/kg/day (2.2 times the highest human dose based on BSA) in mice. In rats, the highest dose used was nephrotoxic, while the highest dose used in mice was subtoxic. Use in patients with fever and infection. The pharmacological activity of Movalis in reducing inflammation and possibly fever may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.